- France
- /
- Professional Services
- /
- ENXTPA:BVI
Here's What Analysts Are Forecasting For Bureau Veritas SA (EPA:BVI) After Its Full-Year Results
A week ago, Bureau Veritas SA (EPA:BVI) came out with a strong set of annual numbers that could potentially lead to a re-rate of the stock. Results were good overall, with revenues beating analyst predictions by 3.8% to hit €6.4b. Statutory earnings per share (EPS) came in at €1.25, some 2.2% above whatthe analysts had expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
View our latest analysis for Bureau Veritas
Taking into account the latest results, the current consensus from Bureau Veritas' 14 analysts is for revenues of €6.69b in 2025. This would reflect a satisfactory 3.8% increase on its revenue over the past 12 months. Per-share earnings are expected to swell 12% to €1.42. Before this earnings report, the analysts had been forecasting revenues of €6.63b and earnings per share (EPS) of €1.38 in 2025. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.
There's been no major changes to the consensus price target of €34.54, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Bureau Veritas analyst has a price target of €40.00 per share, while the most pessimistic values it at €28.50. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Bureau Veritas' past performance and to peers in the same industry. We would highlight that Bureau Veritas' revenue growth is expected to slow, with the forecast 3.8% annualised growth rate until the end of 2025 being well below the historical 6.3% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 5.7% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Bureau Veritas.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Bureau Veritas following these results. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Bureau Veritas' revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Bureau Veritas analysts - going out to 2027, and you can see them free on our platform here.
We don't want to rain on the parade too much, but we did also find 2 warning signs for Bureau Veritas that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if Bureau Veritas might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:BVI
Bureau Veritas
Provides laboratory testing, inspection, and certification services.
Excellent balance sheet with proven track record and pays a dividend.
Similar Companies
Market Insights
Community Narratives


